Short answer: The Soliqua label starts at 15 units once daily for people new to basal insulin or a GLP-1, on a GLP-1, or on under 30 units of basal insulin, and 30 units for people on 30 to 60 units of basal insulin. The dose is adjusted by 2 to 4 units every week based on fasting blood sugar. The range is 15 to 60 units, injected within the hour before the first meal.
This is what the FDA label says. Follow your prescriber. Your prescriber may use a different dose or pace than the label's standard schedule.
What Soliqua is approved for: Soliqua 100/33 is approved, along with diet and exercise, to improve blood sugar control in adults with type 2 diabetes (section 1). The label says it is not recommended with any other product containing a GLP-1 receptor agonist, is not for diabetic ketoacidosis, and has not been studied with mealtime (prandial) insulin.
Source
SOLIQUA 100/33 (insulin glargine and lixisenatide) injection, for subcutaneous use, prescribing information and Medication Guide. Sanofi. DailyMed, version published March 20, 2026. DailyMed setid 4bba538b-cf7c-4310-ae8f-cb711ed21bcc
Soliqua is injected under the skin once a day within the hour before the first meal of the day, in the abdomen, thigh or upper arm. Injection sites are rotated within the same region to lower the risk of lipodystrophy and skin amyloid (sections 2.1, 2.5).
It is not given into a vein or through an insulin pump, not diluted or mixed with any other insulin or solution, and the dose is not split. The pen dials in 1-unit steps (section 2.5).
Each mL has 100 units of insulin glargine and 33 mcg of lixisenatide, in a 3 mL single-patient-use SoloStar pen that delivers 15 to 60 units per injection (sections 2.1, 3).
The table below is the label's schedule, from the Dosage and Administration section. Numbers are copied exactly; the section is in brackets.
| SOLIQUA 100/33 (dose window display) | Insulin glargine component dose | Lixisenatide component dose | Comment |
|---|---|---|---|
| 15 | 15 units | 5 mcg | Recommended starting dosage for patients naive to basal insulin or GLP-1 receptor agonist, currently on GLP-1 receptor agonist, or currently on less than 30 units of basal insulin daily |
| 20 | 20 units | 6.7 mcg | |
| 30 | 30 units | 10 mcg | Recommended starting dosage for patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 receptor agonist |
| 40 | 40 units | 13.3 mcg | |
| 50 | 50 units | 16.7 mcg | |
| 60 | 60 units | 20 mcg | Maximum daily dosage |
The full Table 1 lists every unit from 15 to 60. The dose window shows numbers for even units and lines for odd units. A 2-unit setting is a safety test dose, not for injection.
| Self-Monitored Fasting Plasma Glucose | SOLIQUA 100/33 Dosage Adjustment |
|---|---|
| Above target range | +2 units (2 units of insulin glargine and 0.66 mcg of lixisenatide) to +4 units (4 units of insulin glargine and 1.32 mcg of lixisenatide) |
| Within target range | 0 units |
| Below target range | -2 units (2 units of insulin glargine and 0.66 mcg of lixisenatide) to -4 units (4 units of insulin glargine and 1.32 mcg of lixisenatide) |
The recommended Soliqua dosage is between 15 and 60 units.
Basal insulin or a GLP-1 receptor agonist is stopped before Soliqua is started.
After the starting dose, the dose goes up or down by 2 to 4 units every week based on metabolic needs, blood sugar results and the fasting glucose goal, until the desired fasting glucose is reached.
More adjustment may be needed with changes in physical activity, meal patterns, kidney or liver function, during acute illness, or with other medicines.
The maximum dose is 60 units daily (60 units insulin glargine and 20 mcg lixisenatide). More than 60 units a day can mean an overdose of the lixisenatide part (section 5.5).
Because lixisenatide slows stomach emptying, birth control pills are taken at least 1 hour before Soliqua or 11 hours after. Antibiotics, acetaminophen and other medicines that depend on reaching a set level are taken at least 1 hour before the injection.
Soliqua is not recommended in end-stage kidney disease (eGFR under 15). With kidney or liver impairment, more frequent glucose checks and dose changes may be needed (sections 8.6, 8.7).
In older adults, the label says starting dose, increases and maintenance dose should be conservative to avoid low blood sugar.
If a dose is missed, the once-daily schedule resumes with the next scheduled dose. The label says not to give an extra dose or increase the dose to make up for the missed one.
More on this: missed a dose of Soliqua.
People on basal insulin or a GLP-1 receptor agonist stop it before starting Soliqua. The starting dose is 15 units if they were on a GLP-1 receptor agonist or under 30 units of basal insulin, and 30 units if they were on 30 to 60 units of basal insulin, with or without a GLP-1 receptor agonist.
Using Soliqua with any other product containing lixisenatide or another GLP-1 receptor agonist is not recommended.
In Dose Track you set up Soliqua as a protocol with the dose and schedule your prescriber gave you. A protocol can hold dose steps, each with its own dose and length in days or weeks, so a step-up plan like the one on the label can be entered once and the app moves to the next step on its own. Reminders follow the schedule, and every dose is logged with the date and time, so you can see which step you are on and when your last dose was. The app follows what you enter; it does not choose or change a dose.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.